Lyrica Pfizer Inc. - Treatment for Neuropathic PainLyrica is a 3-substituted analogue of gamma-amino butyric acid (GABA) and a compound related to gabapentin (Neurontin). Lyrica is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN).
Posted: December 2004
- FDA Approves Lyrica CR (pregabalin) Extended-Release Tablets for Neuropathic Pain Conditions - October 12, 2017
- FDA Approves Lyrica For The Management Of Neuropathic Pain Associated With Spinal Cord Injury Based On Priority Review - June 21, 2012
- FDA Approves First Drug for Treating Fibromyalgia - Lyrica - June 22, 2007
- Pfizer Statement on Regulatory Status of Lyrica - September 2, 2004